298 related articles for article (PubMed ID: 19043731)
1. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.
Konstantinidis L; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):311-8. PubMed ID: 19043731
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
3. The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization.
Wu TT; Kung YH
J Ocul Pharmacol Ther; 2012 Apr; 28(2):129-33. PubMed ID: 22066662
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy.
Konstantinidis L; Mantel I; Zografos L; Ambresin A
Eur J Ophthalmol; 2010; 20(5):955-8. PubMed ID: 20306440
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
6. [Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results].
Cornut PL; Poli M; Feldman A; El Chehab H; Swalduz B; Burillon C; Denis P
J Fr Ophtalmol; 2010 May; 33(5):327-33. PubMed ID: 20452098
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients.
Yang X; Dai H
Chin Med J (Engl); 2014; 127(16):2906-10. PubMed ID: 25131225
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
9. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.
Mandal S; Venkatesh P; Sampangi R; Garg S
Eur J Ophthalmol; 2007; 17(4):620-6. PubMed ID: 17671940
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization.
Silva RM; Ruiz-Moreno JM; Nascimento J; Carneiro A; Rosa P; Barbosaa A; Carvalheira F; Abreu JR; Cunha-Vaz JG
Retina; 2008 Oct; 28(8):1117-23. PubMed ID: 18788102
[TBL] [Abstract][Full Text] [Related]
14. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
15. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
Ruiz-Moreno JM; Montero JA; Amat-Peral P
Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.
Wasiluk E; Wojnar M; Obuchowska I; Mariak Z
Int Ophthalmol; 2020 Apr; 40(4):833-839. PubMed ID: 31788714
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
19. Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization.
Wu TT; Kung YH
J Ocul Pharmacol Ther; 2014 Dec; 30(10):837-41. PubMed ID: 25162313
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
